Elsevier

European Journal of Pharmacology

Volume 834, 5 September 2018, Pages 45-53
European Journal of Pharmacology

Molecular and cellular pharmacology
The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC)

https://doi.org/10.1016/j.ejphar.2018.07.006Get rights and content

Abstract

The epithelial-mesenchymal transition (EMT) plays a critical role in cancer progression, metastasis and drug resistance. The transcription factor(TF) and microRNA (miR) chimeric [SNAIL/miR-34]:[ZEB/miR-200] unit is the core regulatory system for the EMT process. Here, we proposed to assess the anti-EMT abilities and explore the inherent pharmacological mechanisms of the classic hypoglycaemic agent metformin for colorectal cancer(CRC).

For the EMT model, the TGF-β-induced CRC cell lines SW480 and HCT116 were treated with metformin. The viability, migration and invasion abilities of the cells were evaluated with the Cell Counting Kit-8, wound-healing and trans-well assay. The alterations of the [SNAIL/miR-34]:[ZEB/miR-200] system and the EMT markers E-cadherin and vimentin were detected by western blot, qPCR and immunofluorescent staining.

Metformin exhibited inhibitory effects on the proliferation, migration and invasion of the CRC SW480 cells. The up-regulation of E-cadherin and the down-regulation of vimentin for both SW480 and HCT116 cells revealed the anti-EMT abilities of metformin. For the [SNAIL/miR-34]:[ZEB/miR-200] system, metformin increased miR-200a, miR-200c and miR-429 levels and decreased miR-34a, SNAIL1 and ZEB1 levels in the TGF-β-induced EMT. From immunofluorescence, we observed increased E-cadherin and ZEB1 co-expression in metformin-treated cells.

Metformin may perform bidirectional regulations of the [SNAIL/miR-34]:[ZEB/miR-200] system in the EMT process for colorectal cancer. Such regulation is expressed as the inhibition of EMT in general as well as an increased higher proportion of E/M hybrid cells in the total population.

Introduction

The epithelial-mesenchymal transition(EMT) is a process in which epithelial cells lose their epithelial characteristics and acquire mesenchymal ones (Peinado et al., 2007). EMT usually occurs in embryogenesis, tissue healing and tumour progression (Armstrong et al., 2011). In pathological practices, EMT has been proven to be associated with the invasion, metastasis and drug resistance of tumour cells (Singh et al., 2010; Christine, 2011). Previous studies found that EMT can be triggered by activating signaling pathways such as Wnt, Notch, TGF, JAK-STAT, etc. (Thiery et al., 2014), and signals from the upstream pathways eventually converge on a core control system which contains two double negative feedback chimaeric regulatory circuits: the upstream circuit SNAIL/miR-34 and the downstream circuit ZEB/miR-200 (Lu et al., 2013). In each circuit, the transcription factor family(ZEB/SNAIL) component and the miRNA family(miR-200/miR34) component act as mutual inhibitors to each other (Burk et al., 2008; Siemens et al., 2011). Based on the interactive mechanism, the SNAIL/miR-34 & ZEB/miR-200 system acts as the master regulator of the EMT process (Berx et al., 2007).

Metformin is a classic hypoglycaemic agent for type 2 diabetes mellitus(DM2) and was proven in the last decade to possess anti-neoplastic activities. In previous clinical studies, metformin was shown to decrease the morbidity (Josie et al., 2005; Libby et al., 2009) and to improve the prognosis (Garrett et al., 2012; Medairos et al., 2016; Gadducci et al., 2016; Lin et al., 2017; Gash et al., 2017; Haukka et al., 2017) for many cancers. In the laboratory, the anti-neoplastic effects were found to be associated with the alterations of several cellular signaling pathways, such as AMPK, mTOR, IGF, etc. (Pollak, 2008; Zakikhani et al., 2008; Vazquez-Martin et al., 2009). In addition, metformin also showed inhibitory effects on the EMT of tumour cells in a few other studies (Cufí et al., 2010; Vazquez-Martin et al., 2010; Zhao et al., 2014; Laskov et al., 2016). However, the exact underlying mechanism of metformin in anti-EMT regulation is still elusive, and the concrete alterations of the [SNAIL/miR-34]:[ZEB/miR-200] core control system are worthwhile to study.

To explore the anti-EMT activities and the mechanisms of metformin, we carried out our study on the human colorectal cancer cell lines SW480 and HCT116. By inducing EMT and by treating with metformin, we tested the EMT extent and detected the alterations of TFs and miRNAs in the [SNAIL/miR-34]:[ZEB/miR-200] system of CRC cells to further discern metformin's pharmacological mechanisms in the EMT process.

Section snippets

Cell culture and reagents

The human colorectal cancer cell lines SW480 and HCT116 were from the Type Culture Collection of the Chinese Academy of Sciences. The cell lines was maintained in RPMI 1640(Corning Inc.) medium containing 10% foetal bovine serum(HyClone, Inc.) at 37 °C in an atmosphere of 5% CO2. Before TGF-β(10 ng/ml, Prepro Tech Inc.) induction, the cells were starved in serum-free RPMI 1640 medium overnight. Metformin was obtained from Solarbio Science﹠Technology Co, stored sealed at −20 °C and dissolved in

Metformin suppresses the proliferation, migration and invasion of human SW480 CRC cells

To testify the inhibitory effect of metformin on CRC cells growth and proliferation, metformin was added by gradient concentration(0, 1, 2, 5, 10 mM) and the viability of the cells detected chronologically(0, 24, 48, 72 h) with a microplate reader using a CCK8 kit. The OD values showed that SW480 cells growth and proliferation were chrono- and dose-dependently inhibited by metformin, consistent with previous studies [Fig. 1B].

In the wound-healing assay, TGF-β(10 ng/ml, 48 h)-induced

Discussion

Colorectal cancer(CRC) is the third most common global cancer. Mainly caused by distant metastasis, CRC is also the fourth highest cause of cancer death worldwide (Ferlay et al., 2015). Previous studies showed decreased miR-200 at the invasive front than at the primary site of CRC, suggesting the role of miR-200 and [SNAIL/miR-34];[ZEB/miR-200] in the EMT, invasion and metastasis of tumours (Hur et al., 2013; Paterson et al., 2013). In our study, metformin exhibited inhibitory effects on the

Funding

This study was funded by the Natural Science Foundation of Shandong Province [Z2005C02] and Science and Technology Development Project of Shandong Province [2014GSF118052].

Conflict of interests

The authors declare that they have no conflict of interests.

Disclosure statement

The authors declare that they have no conflict of interests.

References (66)

  • G. Arunachalam et al.

    Molecular interplay between microRNA-34a and sirtuin1 in hyperglycaemia-mediated impaired angiogenesis in endothelial cells: effects of metformin

    J. Pharmacol. Exp. Ther.

    (2015)
  • G. Berx et al.

    Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer

    Clin. Exp. Metastas-.

    (2007)
  • S. Brabletz et al.

    The ZEB/miR-200 feedback loop—a motor of cellular plasticity in development and cancer?

    EMBO Rep.

    (2010)
  • Brabletz S., Bajdak K., Meidhof S.. et al. 2011. The ZEB1/miR‐200 feedback loop controls Notch signalling in cancer...
  • U. Burk et al.

    A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cells

    Embo Rep.

    (2008)
  • Christine L. Chaffer et al.

    A perspective on cancer cell metastasis

    Science

    (2011)
  • K. Cheng et al.

    Metformin inhibits TGF-β1-induced epithelial-to-mesenchymal transition via PKM2 relative-mTOR/p70s6k signaling pathway in cervical carcinoma cells

    Int. J. Mol. Sci.

    (2016)
  • V. Cosić et al.

    Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?

    Clin. Chem. Lab. Med. Cclm

    (2001)
  • S. Cuf㬠et al.

    Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205

    Cell Cycle

    (2012)
  • S. Cufí et al.

    Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis

    Cell Cycle

    (2010)
  • D. Detaille et al.

    Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process

    Diabetes

    (2005)
  • M.T. Do et al.

    Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents

    Free Radic. Biol. Med.

    (2014)
  • J.M. Evans et al.

    Metformin and reduced risk of cancer in diabetic patients

    BMJ (Clinical Res. ed.)

    (2005)
  • J. Ferlay et al.

    Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

    Int. J. Cancer

    (2015)
  • C. Garofalo et al.

    Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug

    Plos One

    (2013)
  • C.R. Garrett et al.

    Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer

    Br. J. Cancer

    (2012)
  • K.J. Gash et al.

    Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy

    Br. J. Cancer

    (2017)
  • P.A. Gerber et al.

    The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus

    Antioxid. Redox Signal.

    (2016)
  • E. Giovannucci et al.

    Diabetes and cancer: a consensus report

    Ca Cancer J. Clin.

    (2010)
  • S. Hahn et al.

    SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial–mesenchymal transition

    Embo J.

    (2013)
  • X. Han et al.

    Metformin is a novel suppressor for transforming growth factor (TGF)-β1

    Sci. Rep.

    (2016)
  • J. Haukka et al.

    Risk of cause-specific death in individuals with cancer - modifying role diabetes, statins, and metformin

    Int. J. Cancer

    (2017)
  • M. Hu et al.

    Metformin protects H9C2 cardiomyocytes from high-glucose and hypoxia/reoxygenation injury via inhibition of reactive oxygen species generation and inflammatory responses: role of AMPK and JNK

    J. Diabetes Res.

    (2016)
  • Cited by (47)

    • The role of MicroRNA networks in tissue-specific direct and indirect effects of metformin and its application

      2022, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Similarly, studies of colorectal cancer suggest that downregulation of circulating miRNAs belonging to the miR-34 and miR-200 families contributes to EMT and metastatic behavior [187–189]. Metformin prevents colorectal cancer progression by enhancing the expression of miR-34a and miR-200 and inhibiting the overexpression of classical EMT markers such as SNAIL and ZEB [133], suggesting a possible mechanism of action for these circulating miRNAs. On the other hand, the upregulations of miR-34a and miR-200 play a central role in the pathogenesis of tissues.

    • Aspirin facilitates trophoblast invasion and epithelial-mesenchymal transition by regulating the miR-200-ZEB1 axis in preeclampsia

      2021, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Moreover, it was shown that TGF-β1 suppresses E-cadherin expression in the process of EMT, requires the induction of ZEB1/2 and is completely miR-200-dependent [48,53]. Several agents, including decitabine, metformin, PienTze Huang (a traditional Chinese herbal formula) and progesterone, reportedly exert their effects through the ZEB/miR-200 family pathway on lung cancer, colorectal cancer and uterine contractility during pregnancy [48,54–56]. In this study, aspirin was shown to reverse miR-200 family-mediated effects, including the downregulation of epithelial marker expression (E-cadherin) and upregulation of mesenchymal marker expression (ZEB1 and TGF-β1), further leading to the enhancement of trophoblast invasiveness.

    • Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer

      2021, European Journal of Pharmacology
      Citation Excerpt :

      Furthermore, suppression of the EMT inhibitory miRNAs that regulate the epithelial phenotype, is linked to distant metastatic events (Vu and Datta, 2017). In TGF-B induced EMT colon cancer cells, metformin was demonstrated to significantly decrease both SNAIL1 and ZEB1 levels, as well as levels of mesenchymal marker Vimentin (Wang et al., 2018). Inversely, metformin was observed to increase levels of miR-200a, miR-200c, and miR-429 in the EMT-induced CRC cells (Wang et al., 2018).

    • Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53

      2021, Advances in Biological Regulation
      Citation Excerpt :

      It has many effects, potential anti-cancer and other effects. ( Wang et al., 2018). The IC50 of Garcoma cambogia in PANC-28 + pLXSN cells was 60 μg/ml (Fig. 5, Panel C), while the IC50 for PANC-28 + WT-TP53 cells incubated in the presence of Garcinia cambogia was approximately 20-fold lower at 3 μg/ml.

    View all citing articles on Scopus
    View full text